Literature DB >> 35041853

α-synuclein-assisted oligomerization of β-amyloid (1-42).

Edward Chau1, Jin Ryoun Kim2.   

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders, characterized by aggregation of amyloid polypeptides, β-amyloid (Aβ) and α-synuclein (αS), respectively. Aβ and αS follow similar aggregation pathways, starting from monomers, to soluble toxic oligomeric assemblies, and to insoluble fibrils. Various studies have suggested overlaps in the pathologies of AD and PD, and have shown Aβ-αS interactions. Unfortunately, whether these protein-protein interactions lead to self- and co-assembly of Aβ and αS into oligomers - a potentially toxic synergistic mechanism - is poorly understood. Among the various Aβ isoforms, interactions of Aβ containing 42 amino acids (Aβ (1-42), referred to as Aβ42) with αS are of most direct relevance due to the high aggregation propensity and the strong toxic effect of this Aβ isoform. In this study, we carefully determined molecular consequences of interactions between Aβ42 and αS in their respective monomeric, oligomeric, and fibrillar forms using a comprehensive set of experimental tools. We show that the three αS conformers, namely, monomers, oligomers and fibrils interfered with fibrillization of Aβ42. Specifically, αS monomers and oligomers promoted oligomerization and stabilization of soluble Aβ42, possibly via direct binding or co-assembly, while αS fibrils hindered soluble Aβ42 species from converting into insoluble aggregates by the formation of large oligomers. We also provide evidence that the interactions with αS were mediated by various parts of Aβ42, depending on Aβ42 and αS conformers. Furthermore, we compared similarities and dissimilarities between Aβ42-αS and Aβ40-αS interactions. Overall, the present study provides a comprehensive depiction of the molecular interplay between Aβ42 and αS, providing insight into its synergistic toxic mechanism.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aggregation; Alpha-synuclein; Beta-amyloid; Oligomer; Protein-protein interaction

Mesh:

Substances:

Year:  2022        PMID: 35041853      PMCID: PMC8818042          DOI: 10.1016/j.abb.2022.109120

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  88 in total

1.  On the nature of the multivalency effect: a thermodynamic model.

Authors:  Pavel I Kitov; David R Bundle
Journal:  J Am Chem Soc       Date:  2003-12-31       Impact factor: 15.419

Review 2.  Effects of in vivo conditions on amyloid aggregation.

Authors:  Michael C Owen; David Gnutt; Mimi Gao; Sebastian K T S Wärmländer; Jüri Jarvet; Astrid Gräslund; Roland Winter; Simon Ebbinghaus; Birgit Strodel
Journal:  Chem Soc Rev       Date:  2019-07-15       Impact factor: 54.564

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

Authors:  E Masliah; E Rockenstein; I Veinbergs; Y Sagara; M Mallory; M Hashimoto; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

5.  Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.

Authors:  A Heyman; G G Fillenbaum; M Gearing; S S Mirra; K A Welsh-Bohmer; B Peterson; C Pieper
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

6.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

7.  Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.

Authors:  Yuesong Gong; Lei Chang; Kirsten L Viola; Pascale N Lacor; Mary P Lambert; Caleb E Finch; Grant A Krafft; William L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

8.  Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.

Authors:  Gal Bitan; Marina D Kirkitadze; Aleksey Lomakin; Sabrina S Vollers; George B Benedek; David B Teplow
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-27       Impact factor: 11.205

Review 9.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

Review 10.  Seeking a mechanism for the toxicity of oligomeric α-synuclein.

Authors:  Hazel L Roberts; David R Brown
Journal:  Biomolecules       Date:  2015-03-25
View more
  1 in total

1.  Real-Time Fast Amyloid Seeding and Translocation of α-Synuclein with a Nanopipette.

Authors:  Nathan Meyer; Jean-Marc Janot; Joan Torrent; Sébastien Balme
Journal:  ACS Cent Sci       Date:  2022-02-23       Impact factor: 18.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.